Sridhar Mani

Summary

Affiliation: Montefiore Medical Center
Country: USA

Publications

  1. doi request reprint Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR)
    Bhaskar C Das
    Albert Einstein Cancer Center, Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, NY 10463, USA
    Bioorg Med Chem Lett 18:3974-7. 2008
  2. ncbi request reprint Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism
    Radharani Gollamudi
    Montefiore Medical Center and the Albert Einstein College of Medicine and Cancer Center, Bronx, NY 10461, USA
    Curr Drug Metab 9:611-3. 2008
  3. ncbi request reprint Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I
    S Mani
    Albert Einstein College of Medicine, Department of Oncology, Bronx, New York 10461, USA
    Ann N Y Acad Sci 1002:252-62. 2003
  4. ncbi request reprint Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies
    S Mani
    University of Chicago Medical Center, Section of Hematology Oncology, Chicago, Illinois, USA
    Cancer 92:1567-76. 2001
  5. ncbi request reprint Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer
    Sridhar Mani
    Department of Medicine, Section of Hematology Oncology, Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 8:1042-8. 2002
  6. ncbi request reprint Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents
    Sridhar Mani
    Albert Einstein Cancer Center and Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Clin Cancer Res 11:6359-69. 2005
  7. doi request reprint Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer
    S Mani
    Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Drugs Today (Barc) 46:641-53. 2010
  8. ncbi request reprint Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone
    S Mani
    The Albert Einstein Comprehensive Cancer Center, Department of Molecular Genetics, Albert Einstein College of Medicine, New York University, and Department of Oncology, Weiler Hospital, Bronx, NY 10461, USA
    Ann Oncol 18:190-5. 2007
  9. ncbi request reprint Novel combinations with oxaliplatin
    S Mani
    Department of Medicine and Oncology, Montefiore Medical Center, Albert Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, New York, USA
    Oncology (Williston Park) 14:52-8. 2000
  10. ncbi request reprint Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer
    S Mani
    University of Chicago Cancer Research Center, Chicago, IL, USA
    J Clin Oncol 18:2894-901. 2000

Research Grants

Collaborators

Detail Information

Publications91

  1. doi request reprint Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR)
    Bhaskar C Das
    Albert Einstein Cancer Center, Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, NY 10463, USA
    Bioorg Med Chem Lett 18:3974-7. 2008
    ..This is the first demonstration of a chemical analog of a PXR inhibitor that retains activity against activated PXR. Furthermore, in contrast with ketoconazole, 3 is less toxic in human cell lines and has negligible CYP450 activity...
  2. ncbi request reprint Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism
    Radharani Gollamudi
    Montefiore Medical Center and the Albert Einstein College of Medicine and Cancer Center, Bronx, NY 10461, USA
    Curr Drug Metab 9:611-3. 2008
    ....
  3. ncbi request reprint Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I
    S Mani
    Albert Einstein College of Medicine, Department of Oncology, Bronx, New York 10461, USA
    Ann N Y Acad Sci 1002:252-62. 2003
    ..g., camptothecins). Phase I combination studies are currently underway to further explore the clinical, pharmacokinetic, and biologic profile of GEM 231 with chemotherapy...
  4. ncbi request reprint Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies
    S Mani
    University of Chicago Medical Center, Section of Hematology Oncology, Chicago, Illinois, USA
    Cancer 92:1567-76. 2001
    ..The purpose of this study was to determine the maximum tolerated dose and toxicity profile of gemcitabine given on a weekly schedule with continuous infusion 5-fluorouracil...
  5. ncbi request reprint Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer
    Sridhar Mani
    Department of Medicine, Section of Hematology Oncology, Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 8:1042-8. 2002
    ..Our study warrants further exploration of efficacy in a Phase II and/or Phase III clinical trial setting...
  6. ncbi request reprint Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents
    Sridhar Mani
    Albert Einstein Cancer Center and Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Clin Cancer Res 11:6359-69. 2005
    ..This report describes studies undertaken to explore the characteristics of hPXR stimulation and mechanisms of drug-receptor interactions in vitro with new anti-tubulin drugs...
  7. doi request reprint Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer
    S Mani
    Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Drugs Today (Barc) 46:641-53. 2010
    ..It appears to be a suitable candidate for third-line monotherapy and beyond for locally advanced and metastatic breast cancer. This review will focus on published and peer-reviewed data on breast cancer...
  8. ncbi request reprint Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone
    S Mani
    The Albert Einstein Comprehensive Cancer Center, Department of Molecular Genetics, Albert Einstein College of Medicine, New York University, and Department of Oncology, Weiler Hospital, Bronx, NY 10461, USA
    Ann Oncol 18:190-5. 2007
    ..In the current study, a new expanded evaluation of drug target effect was undertaken...
  9. ncbi request reprint Novel combinations with oxaliplatin
    S Mani
    Department of Medicine and Oncology, Montefiore Medical Center, Albert Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, New York, USA
    Oncology (Williston Park) 14:52-8. 2000
    ....
  10. ncbi request reprint Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer
    S Mani
    University of Chicago Cancer Research Center, Chicago, IL, USA
    J Clin Oncol 18:2894-901. 2000
    ..To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer...
  11. ncbi request reprint Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors
    Sridhar Mani
    Albert Einstein College of Medicine, Department of Molecular Pharmacology, and Albert Einstein Comprehensive Cancer Center, Bronx, New York 10461, USA
    Clin Cancer Res 10:1289-98. 2004
    ..The purpose of this study was to determine the maximum tolerated dose, toxicity, and pharmacokinetics of BMS-247550 administered as a 1-h i.v. infusion every 3 weeks...
  12. ncbi request reprint Oxaliplatin: a review of evolving concepts
    Sridhar Mani
    Department of Oncology, Weiler Hospital Montefiore Medical Center, Albert Einstein Cancer Center of the Albert Einstein College of Medicine, Room 2S 63, 1825 Eastchester Road, Bronx, NY 10461, USA
    Cancer Invest 20:246-63. 2002
  13. ncbi request reprint A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers
    Sanjay Goel
    Albert Einstein Cancer Center, Bronx, NY, USA
    Invest New Drugs 24:125-34. 2006
    ..Preclinical studies have demonstrated synergistic antitumor activity when GEM231 is combined with docetaxel. This trial assesses the safety of this combination...
  14. ncbi request reprint A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines
    Kongming Wu
    Albert Einstein Comprehensive Cancer Center, Department of Medicine, Albert Einstein College of Medicine, Chanin 302, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Invest New Drugs 23:299-309. 2005
    ..The synergy of Flavopiridol and UCN-01 are selectively toxic to survivin-overexpressing cell lines and the mechanism of toxicity involves caspase-dependent cell death...
  15. ncbi request reprint Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers
    Sanjay Goel
    Department of Oncology, Albert Einstein College of Medicine and Cancer Center, Bronx, NY 10461, USA
    Invest New Drugs 25:237-45. 2007
    ..We conducted a study to identify a safe dose and potential drug-drug interactions of this combination...
  16. pmc Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma
    Anthony P Lam
    New York Cancer Consortium www newyorkcancerconsortium org, including the Montefiore Einstein Cancer Center, Bronx, NY 10461, USA
    Am J Clin Oncol 33:121-4. 2010
    ..To determine the efficacy and toxicity of the protein kinase C inhibitor bryostatin-1 plus paclitaxel in patients with advanced pancreatic carcinoma...
  17. pmc Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR
    Hao Li
    Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Biol Chem 288:13655-68. 2013
    ..Ketoconazole binds to and antagonizes pregnane X receptor (PXR) activation...
  18. pmc Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice
    Hongwei Wang
    Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, New York 10461, USA
    J Clin Invest 121:3220-32. 2011
    ..Taken together, these data indicate that colon cancer growth in the presence of a specific PXR ligand results from tumor-specific induction of FGF19. These observations may lead to improved therapeutic regimens for colon carcinomas...
  19. pmc Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen
    Velasco Cimica
    Department of Genetics, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461, USA
    BMC Cancer 10:634. 2010
    ....
  20. ncbi request reprint A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma
    Della Makower
    Department of Oncology, Montefiore Medical Center Albert Einstein Cancer Center, 111 E 210 Street, Bronx, NY 10467, USA
    Cancer Invest 21:177-84. 2003
    ..5 weeks (range 14.5-28+). Edrecolomab and capecitabine may be safely given in combination to patients with advanced or metastatic adenocarcinoma. Clinical activity is seen in this heavily pretreated patient population...
  21. ncbi request reprint Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma
    Minaxi Jhawer
    Montefiore Medical Center, NY, USA
    Invest New Drugs 25:85-94. 2007
    ..To evaluate the tolerability and efficacy of nolatrexed in patients with advanced hepatocellular carcinoma...
  22. ncbi request reprint A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital
    Federico Innocenti
    Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, IL 60637, USA
    Clin Pharmacol Ther 76:490-502. 2004
    ..Five partial responses were observed. Pharmacokinetic modulation of irinotecan with cyclosporine and phenobarbital has been demonstrated; further studies are necessary to evaluate whether this strategy improves the therapeutic index...
  23. ncbi request reprint Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer
    Apurva A Desai
    Section of Hematology Oncology, University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 56:421-6. 2005
    ..Hence, we conducted this phase II trial in patients with colorectal cancer (CRC) to further evaluate the toxicity and activity of irinotecan modulated with cyclosporine...
  24. ncbi request reprint Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers
    Hedy L Kindler
    Section of Hematology Oncology, University of Chicago Medical Center, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Invest New Drugs 23:489-93. 2005
    ..We conducted 2 parallel phase II trials of dolastatin-10 in patients with advanced hepatobiliary cancers and pancreatic adenocarcinoma...
  25. ncbi request reprint UCN-01 alters phosphorylation of Akt and GSK3beta and induces apoptosis in six independent human neuroblastoma cell lines
    Sai Latha Shankar
    Department of Pathology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Neurochem 90:702-11. 2004
    ..Thus, UCN-01 was effective at inducing apoptosis in neuroblastoma cell lines...
  26. doi request reprint Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer
    Divya Gupta
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Women s Health, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 10461, USA
    Clin Cancer Res 14:5332-40. 2008
    ..We examined the presence of the pregnane X receptor (PXR) and its effects on ovarian cancer cells after activation by its cognate ligand...
  27. ncbi request reprint A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer
    Sanjay Goel
    Department of Oncology, Montefiore Medical Center, Bronx, NY 10461, USA
    Invest New Drugs 21:103-7. 2003
    ....
  28. ncbi request reprint The clinical development of new mitotic inhibitors that stabilize the microtubule
    Sridhar Mani
    Departments of Medicine and Oncology, Albert Einstein College of Medicine, Montefiore and Jacobi Medical Center, Bronx, NY, USA
    Anticancer Drugs 15:553-8. 2004
    ..There is now considerable data regarding the efficacy of the epothilones in human beings and discodermolide holds such promise, as well...
  29. doi request reprint Rhabdoid tumor growth is inhibited by flavopiridol
    Melissa E Smith
    Department of Molecular Genetics, Albert Einstein College Cancer Center, Bronx, NY 10461, USA
    Clin Cancer Res 14:523-32. 2008
    ..Because cdk inhibitors have not been used for preclinical or clinical testing on rhabdoid tumors, we investigated the effect of flavopiridol, a pan-cdk inhibitor with promising clinical activity, on rhabdoid tumors...
  30. ncbi request reprint Activated pregnenolone X-receptor is a target for ketoconazole and its analogs
    Hongwei Wang
    Albert Einstein Cancer Center, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Clin Cancer Res 13:2488-95. 2007
    ..Because the orphan receptor, pregnenolone X-receptor (PXR), coordinately regulates the expression of paclitaxel metabolizing and transport enzymes, controlling this process could improve therapeutic outcome...
  31. pmc Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics
    Bhaskar C Das
    Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Bioorg Med Chem Lett 19:4204-6. 2009
    ..We are in the process to explore the molecular mechanism of action of oxazine derivative compounds on hypoxia tumor cells...
  32. ncbi request reprint Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors
    Gregory A Masters
    Feinberg School of Medicine of Northwestern University, Evanston Northwestern Healthcare, Evanston, IL, USA
    Med Oncol 20:7-12. 2003
    ..The docetaxel dose can be safely escalated to 145 mg/m(2) every 21 d with GCSF support, a 45% increase above the standard recommended phase II dose. Further studies will clarify the role of dose-intensified docetaxel...
  33. doi request reprint A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies
    Sanjay Goel
    Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Clin Cancer Res 15:4207-12. 2009
    ..This phase I study determined the maximum tolerated dose (MTD) and pharmacokinetics of eribulin administered on a 3 of 4 week schedule in patients with advanced solid malignancies...
  34. doi request reprint Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: a single institution experience from 1999 to 2010
    June Y Hou
    Montefiore Medical Center, Bronx, NY, USA Albert Einstein College of Medicine, Bronx, NY, USA Department of Obstetrics and Gynecology, and Women s Health, Division of Gynecology Oncology, Albert Einstein College of Medicine, Bronx, NY, USA
    Gynecol Oncol 131:163-8. 2013
    ..The objective of this study was to assess toxicity, clinical benefit and prognosticators in gynecologic oncology patients participating in phase 1 trials...
  35. pmc Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions
    Sridhar Mani
    Albert Einstein College of Medicine, Albert Einstein Cancer Center, Bronx, NY 10461, USA
    Expert Opin Drug Metab Toxicol 5:109-30. 2009
    ..However, in the era of 'targeted' or seemingly 'less toxic' therapy, these interactions are more commonly flagged and contribute significantly towards poor 'quality of life' and medical fatalities...
  36. ncbi request reprint The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor
    Hongwei Wang
    Albert Einstein College of Medicine, Albert Einstein Cancer Center, Bronx, New York 10461, USA
    Mol Endocrinol 22:838-57. 2008
    ..These studies provide the basis for development of novel small molecule inhibitors of PXR with the ultimate goal of clinical applications toward preventing drug-drug interactions...
  37. ncbi request reprint Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies
    Sanjay Goel
    Department of Hematology Oncology, Montefiore Medical Center Albert Einstein College of Medicine and Albert Einstein Comprehensive Cancer Center Bronx, NY 10461, USA
    Am J Clin Oncol 25:528-34. 2002
    ..The combination of irinotecan 275 mg/m(2) and capecitabine 2,300 mg/d represents a safe, favorable, and convenient outpatient regimen warranting further phase II evaluation...
  38. ncbi request reprint Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors
    Samir D Undevia
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Invest New Drugs 22:449-58. 2004
    ..The recommended phase II dose is 256 mg/m(2)/d. Rapid dose escalation with single patient cohorts was a safe and efficient method of conducting this phase I trial...
  39. pmc Alleviation of gut inflammation by Cdx2/Pxr pathway in a mouse model of chemical colitis
    Wei Dou
    Department of Medicine, Albert Einstein College of Medicine, New York, New York, United States of America
    PLoS ONE 7:e36075. 2012
    ..Pharmacological targeting of intestinal PXR using natural metabolically labile ligands could serve as effective and potent therapeutics for gut inflammation that avert systemic drug interactions...
  40. ncbi request reprint Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 57:465-74. 2006
    ..The pharmacokinetics of MGd were also evaluated...
  41. ncbi request reprint A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors
    Sanjay Goel
    Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Clin Cancer Res 9:4069-76. 2003
    ..The purpose of this study was to define the safety and pharmacodynamics of GEM231, a mixed backbone antisense oligonucleotide targeting the type I regulatory subunit alpha of protein kinase A, administered as a continuous i.v. infusion...
  42. pmc Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors
    Radharani Gollamudi
    Department of Oncology, Montefiore Medical Center, Bronx, NY, USA
    Invest New Drugs 28:641-9. 2010
    ..It induces cytopathic and anti-cancer effects in cells with an activated ras pathway due to inhibition of the dsRNA-activated protein kinase...
  43. ncbi request reprint The efficacy and safety of ixabepilone monotherapy in the treatment of breast and gynecologic malignancies
    Divya Gupta
    Montefiore Medical Center, Albert Einstein College of Medicine, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women s Health, Bronx, NY 10461, USA
    Expert Opin Drug Saf 8:81-8. 2009
    ..Clinical studies demonstrate significant activity of ixabepilone monotherapy in these heavily pretreated patients. The toxicity profile of ixabepilone seems to be similar to that of taxanes and manageable by supportive methods...
  44. doi request reprint The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development
    Sanjay Goel
    Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Clin Cancer Res 14:2701-9. 2008
    ..To determine if ixabepilone is a substrate for cytochrome P450 3A4 (CYP3A4) and if its metabolism by this cytochrome is clinically important, we did a clinical drug interaction study in humans using ketoconazole as an inhibitor of CYP3A4...
  45. ncbi request reprint Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase
    Anca M Bulgaru
    Montefiore Medical Center, Department of Oncology, Bronx, NY 10467, USA
    Expert Rev Anticancer Ther 3:269-79. 2003
    ..This drug has demonstrated promising antitumor activity in Phase II trials in several solid tumors and definitive Phase III studies to demonstrate clinical benefit have completed accrual...
  46. ncbi request reprint The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics
    WenJing Liu
    Albert Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Curr Med Chem Anticancer Agents 3:217-23. 2003
    ..This rationale becomes even more striking when one observes overexpression of Bcl2 in 70% of breast cancer, 30-60% of prostate cancer, 80% of B-cell lymphomas, 90% of colorectal adenocarcinomas, and many other forms of cancer...
  47. ncbi request reprint Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study
    Hayley M McDaid
    Departments of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Clin Cancer Res 8:2035-43. 2002
    ..Cell death occurred 23 h after peak microtubule bundle formation in these tumor cells. These findings validate in vitro pharmacodynamic observations...
  48. ncbi request reprint Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer
    C M Rudin
    Section of Hematology Oncology, University of Chicago Medical Center, Chicago, Illinois 60637 1470, USA
    Clin Cancer Res 7:1214-20. 2001
    ....
  49. ncbi request reprint A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer
    R L Schilsky
    Biological Sciences Division, University of Chicago, Illinois 60637, USA
    Ann Oncol 11:415-20. 2000
    ..To evaluate the safety and efficacy of a five-day regimen of oral 5-fluorouracil (5-FU) plus eniluracil (776C85) in patients with metastatic colorectal cancer (CRC)...
  50. ncbi request reprint Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil
    Dale R Shepard
    University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 49:398-402. 2002
    ..To determine the effect of food on the pharmacokinetics of 5-fluoruracil (5-FU) taken orally with eniluracil and to compare the performance of different pharmacokinetic analysis methods in the detection a potential food-drug interaction...
  51. ncbi request reprint 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium
    Hedy L Kindler
    Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Invest New Drugs 22:323-7. 2004
    ..Grade 3 nausea and fatigue each developed in 7% of patients. We conclude that 9-AC given by 120-hour continuous infusion demonstrates no clinical activity in patients with metastatic gastric cancer...
  52. ncbi request reprint Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations
    B C Goh
    Section of Hematology/Oncology, Cancer Research Center, University of Chicago, Chicago, IL, USA
    J Clin Oncol 19:1476-84. 2001
    ..CONCLUSION: The recommended dose for ZD9331 on this schedule is 25 mg/d. Neutropenia, thrombocytopenia, and rash were dose-limiting, and efficacy studies in colorectal cancer are indicated...
  53. ncbi request reprint Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors
    S Goel
    Department of Oncology, Albert Einstein Comprehensive Cancer Center and Montefiore Medical Center, New York, NY, USA
    Ann Oncol 14:1682-7. 2003
    ..The aim of this study was to determine the maximum tolerated dose, recommended phase II dose (RPTD) and toxicities of the FOG regimen (infusional 5-fluorouracil, oxaliplatin, gemcitabine)...
  54. ncbi request reprint Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis
    Umang Swami
    Internal Medicine, St Barnabas Hospital, Bronx, NY 10457, USA
    Curr Drug Targets 14:777-97. 2013
    ....
  55. pmc PXR antagonists and implication in drug metabolism
    Sridhar Mani
    Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Drug Metab Rev 45:60-72. 2013
    ..Further work in the future is needed to fully define potent, more-selective PXR antagonists that may be useful in clinical application...
  56. ncbi request reprint Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways
    Kongming Wu
    Division of Hormone Dependent Tumor Biology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Mol Cancer Ther 1:695-706. 2002
    ..Cyclin D1 overexpression results in combination drug resistance. In addition, inhibition of Akt may prove to be a useful therapeutic strategy in combination with flavopiridol...
  57. pmc Acetylation of pregnane X receptor protein determines selective function independent of ligand activation
    Arunima Biswas
    Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Biochem Biophys Res Commun 406:371-6. 2011
    ..Most importantly, the acetylation status of PXR regulates its selective function independent of ligand activation...
  58. pmc Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone
    S Goel
    Department of Oncology, Albert Einstein College of Medicine and Cancer Center, Bronx, NY, USA
    Ann Oncol 19:2048-52. 2008
    ..We expanded the cohort at the RPTD to include detailed assessment of nerve damage in these patients. We report our findings on vibration perception threshold (VPT) and neuropathy...
  59. ncbi request reprint The Cockayne syndrome group B DNA repair protein as an anti-cancer target
    Y Lu
    Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Int J Oncol 19:1089-97. 2001
    ..Collectively, these results suggest that the CSB gene product may be viewed as an anti-cancer target...
  60. ncbi request reprint Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineere monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors
    S Goel
    Albert Einstein Cancer Center, New York, NY, USA
    Ann Oncol 18:1704-7. 2007
    ....
  61. ncbi request reprint Antisense strategies for oncogene inactivation
    C A Stein
    Department of Oncology, Albert Einstein Montefiore Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA
    Semin Oncol 32:563-72. 2005
    ..While the application of antisense technology to the treatment of human cancer is conceptually straightforward, in practice there are many complicated, mechanistically based questions that must be considered...
  62. ncbi request reprint Phase II study of flavopiridol in patients with advanced colorectal cancer
    M Aklilu
    Department of Medicine, University of Chicago, Chicago, IL, USA
    Ann Oncol 14:1270-3. 2003
    ..We evaluated flavopiridol in a phase II trial in patients with previously untreated advanced colorectal cancer (ACRC)...
  63. ncbi request reprint Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282
    Minaxi Jhawer
    Department of Oncology, Montefiore Medical Center, Weiler Hospital, Room 2S 49, 1825 Eastchester Road, Bronx, NY 10461, USA
    Invest New Drugs 24:447-54. 2006
    ..This regimen and sequence is worthy of further study especially in combination with colony stimulating factors, however, its tolerability may be most applicable for patients who have had minimal prior therapy...
  64. ncbi request reprint A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma
    Cathy Eng
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Am J Clin Oncol 27:565-9. 2004
    ..Grade 3/4 nonhematologic toxicities were minimal. We conclude that fixed dose rate gemcitabine results in significant myelosuppression and has minimal activity in patients with biliary tree carcinoma...
  65. pmc In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation
    Madhukumar Venkatesh
    Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, New York, USA
    Mol Pharmacol 80:124-35. 2011
    ..This class of agents is suitable for development as chemical probes of PXR function as well as potential PXR-directed therapeutics...
  66. pmc Orphan nuclear receptors as targets for drug development
    Subhajit Mukherjee
    Department of Medicine, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Chanin 302 D1, Bronx, New York 10461, USA
    Pharm Res 27:1439-68. 2010
    ..In this review, we will highlight these receptors in several physiologic and pathophysiologic actions and demonstrate how their functions can be exploited for the successful development of newer drugs...
  67. pmc Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists
    Arunima Biswas
    Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Pharm Res 26:1807-15. 2009
    ..Based on this review it will be clear that antagonists of PXR and PXR-like pathways will have widespread utility in PXR biology and therapeutics...
  68. ncbi request reprint Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma
    S Mani
    Hematology Oncology, University of Chicago Pritzker School of Medicine, IL, USA
    Invest New Drugs 17:97-101. 1999
    ..UFT 300 mg/m2/day and leucovorin 90 mg/day could be administered safely to patients with advanced biliary cancer with good performance status; however, this combination and schedule of 28-day administration has no activity in this disease...
  69. ncbi request reprint Current approaches to novel therapeutics in pancreatic cancer
    Corina E Akerele
    Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York 10461, USA
    Invest New Drugs 21:113-29. 2003
    ..The article discusses the current knowledge of the biology of this lethal disease, its impact on treatment options, and explores novel therapeutic modalities that are likely to improve outcomes and survival for patients in the future...
  70. ncbi request reprint Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer
    N J Vogelzang
    Cancer Research Center, University of Chicago Pritzker School of Medicine, Illinois 60637 1470, USA
    Clin Cancer Res 4:929-34. 1998
    ..Curiously, an increase in alkaline phosphatase was associated with an increase in the platelet nadir (P = 0.02). If PZDH continues to be developed as an antineoplastic agent, further studies of these relationships are suggested...
  71. pmc Methodologies to decipher the cell secretome
    Paromita Mukherjee
    Department of Genetics, Albert Einstein College of Medicine, Bronx, New York, 10461, USA Electronic address
    Biochim Biophys Acta 1834:2226-32. 2013
    ..This review is a part of a Special issue on The Secretome. This article is part of a Special Issue entitled: An Updated Secretome. ..
  72. doi request reprint Sixth International Congress on Shwachman-Diamond syndrome: from patients to genes and back
    Johnson M Liu
    The Feinstein Institute for Medical Research, North Shore Long Island Jewish Health System, New York, USA
    Ann N Y Acad Sci 1242:26-39. 2011
    ....
  73. ncbi request reprint Tyrosine kinase inhibitors: a clinical perspective
    Sanjay Goel
    Division of Oncology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA
    Curr Oncol Rep 4:9-19. 2002
    ..Other uses are being tested, such as imatinib for gastrointestinal stromal tumor. These compounds will alter cancer care as adjuncts to currently available treatment options...
  74. ncbi request reprint Histone acetylation and the cell-cycle in cancer
    C Wang
    The Albert Einstein Comprehensive Cancer Center, Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Chanin 302, 1300 Morris Park Ave, Bronx, NY 10461, USA
    Front Biosci 6:D610-29. 2001
    ....
  75. ncbi request reprint Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer
    R B Ewesuedo
    Committee on Clinical Pharmacology, Section of Pediatric Hematology-Oncology, Department of Pediatrics, University of Chicago, IL 60637, USA
    J Clin Oncol 19:2084-90. 2001
    ..Further studies to characterize the pharmacodynamics and pharmacogenetics of TAS-103 are warranted...
  76. ncbi request reprint Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer
    R L Schilsky
    Department of Medicine, Cancer Research Center and Committee on Clinical Pharmacology, University of Chicago, Illinois 60637, USA
    Clin Cancer Res 6:3025-31. 2000
    ..Bone marrow suppression, which may be cumulative, is the dose-limiting toxicity of the combination. Prolonged AGT suppression is likely attributable primarily to the effect of O6-benzyl-8-oxoguanine...
  77. ncbi request reprint Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors
    D Alarcon-Vargas
    Department of Molecular Genetics, Albert Einstein College of Medicine, New York, NY, USA
    Oncogene 25:722-34. 2006
    ..These results demonstrate that 4-HPR and tamoxifen are effective chemotherapeutic agents for RTs. We propose that downmodulation of cyclin D1 is a novel and effective therapeutic strategy for RTs...
  78. ncbi request reprint Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways
    S L Shankar
    Department of Pathology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Neurochem 79:426-36. 2001
    ....
  79. ncbi request reprint Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group
    Chris H Takimoto
    Medicine Branch at Navy, National Naval Medical Center, National Cancer Institute, Bethesda, MD, USA
    Semin Oncol 30:20-5. 2003
    ..These data suggest that dose reductions of single-agent oxaliplatin are not necessary in patients with CrCLs >20 mL/min...
  80. ncbi request reprint Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study
    Timothy W Synold
    City of Hope Comprehensive Cancer Center, Duarte, California, USA
    Clin Cancer Res 13:3660-6. 2007
    ..To determine the toxicities, pharmacokinetics, and maximally tolerated doses of oxaliplatin in patients with hepatic impairment and to develop formal guidelines for oxaliplatin dosing in this patient population...
  81. ncbi request reprint Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group
    James H Doroshow
    Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Semin Oncol 30:14-9. 2003
    ....
  82. ncbi request reprint Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function
    Chris H Takimoto
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 13:4832-9. 2007
    ..To characterize the pharmacokinetics and pharmacodynamics of oxaliplatin in cancer patients with impaired renal function...
  83. pmc Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites
    Sean Ekins
    ACT LLC, 601 Runnymede Avenue, Jenkintown, PA 19046, USA
    Mol Pharmacol 72:592-603. 2007
    ..These observations bear significant implications for future discovery of molecules that are more selective and potent antagonists...
  84. ncbi request reprint Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
    Chris H Takimoto
    University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center, 7979 Wurzbach Rd, Room Z415, San Antonio, TX 78229, USA
    J Clin Oncol 21:2664-72. 2003
    ..This study was undertaken to determine the toxicities, pharmacokinetics, and maximum tolerated doses of oxaliplatin in patients with renal impairment and to develop formal guidelines for oxaliplatin dosing in this patient population...
  85. ncbi request reprint Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors
    William C Zamboni
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA
    Cancer Chemother Pharmacol 57:631-9. 2006
    ..Thus, we evaluated the disposition of 9NC and 9AC after administration of 9NC under fasting conditions and after a standard meal...
  86. doi request reprint Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
    Joseph Gibbons
    Case Comprehensive Cancer Center, Ireland Cancer Center at University Hospitals of Case Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH, USA
    J Clin Oncol 26:570-6. 2008
    ....
  87. ncbi request reprint Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes
    William C Zamboni
    Hillman Cancer Research Center, Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Invest New Drugs 24:393-401. 2006
    ..The aim of this study was to evaluate the functional consequence of known single nucleotide polymorphisms in the transporter genes ABCB1, ABCC2, and ABCG2 on the pharmacokinetic disposition of 9NC and 9AC...
  88. ncbi request reprint TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors
    Neil Senzer
    US Oncology, Dallas, TX, USA
    J Clin Oncol 22:592-601. 2004
    ..The goals of this study were to determine the safety and toxicity of TNFerade in combination with radiation therapy...
  89. ncbi request reprint Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs
    Gregory A Otterson
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
    Clin Cancer Res 13:1246-52. 2007
    ..To evaluate the toxicity profile of inhalational doxorubicin in patients with malignant disease in the lung...
  90. doi request reprint Computational discovery of novel low micromolar human pregnane X receptor antagonists
    Sean Ekins
    Collaborations in Chemistry, Jenkintown, PA 19046, USA
    Mol Pharmacol 74:662-72. 2008
    ..8 microM), that seems to be a PXR antagonist in vitro. These observations are important for predicting whether further molecules may interact with PXR as antagonists in vivo with potential therapeutic applications...
  91. ncbi request reprint Autoantibody cancer biomarker: extracellular protein kinase A
    Maria V Nesterova
    Cellular Biochemistry Section, Basic Research Laboratory, National Cancer Institute, Bethesda, MD 20892 1750, USA
    Cancer Res 66:8971-4. 2006
    ..Our results show that autoantibody ECPKA is a universal serum biomarker for cancers of various cell types...

Research Grants2

  1. Chemical Modulation of Orphan Nuclear Receptor Function
    Sridhar Mani; Fiscal Year: 2010
    ..These studies will be vital for the generation on non-toxic compounds that antagonize PXR function - a tool necessary to probe PXR function in cells. ..
  2. Chemical Modulation of Orphan Nuclear Receptor Function
    Sridhar Mani; Fiscal Year: 2009
    ..These studies will be vital for the generation on non-toxic compounds that antagonize PXR function - a tool necessary to probe PXR function in cells. ..